Last updated: October 31, 2021
Sponsor: Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.
Overall Status: Active - Recruiting
Phase
N/A
Condition
Hepatitis B
Scar Tissue
Hepatic Fibrosis
Treatment
N/AClinical Study ID
NCT05106972
SCT20181032
Ages 20-60 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Aged between 20 and 60 (male or female)
- Diagnosed chronic decompensated hepatitis B cirrhosis with a course of more than 5years
- Not suitable for liver transplantation or there is no donor liver source
- No serious bleeding tendency or active bleeding
- No hepatic encephalopathy
- After strict medical conservative treatment for more than 6 months, there was norelief of symptoms or significant improvement of quality of life score
- Subjects voluntarily participate in this study and sign informed consent
Exclusion
Exclusion Criteria:
- Be less than 20 years old or more than 60 years old
- Cirrhosis caused by other causes such as alcoholic hepatitis, hepatitis C virus andautoimmune hepatitis
- Found liver malignant tumor or the family history of liver malignant tumor in thethird generation of their direct relatives
- Patients with hypersplenism who need splenectomy
- History of tumors in other organs
- PT prolongation is greater than 3 seconds
- Use of human serum albumin within 3 weeks prior to clinical registration
- Clinically significant upper gastrointestinal bleeding events occurred within 4 weeksbefore clinical registration
- Spontaneous peritonitis
- Active infection (viral or bacterial)
- Pregnant or lactating women
- The researcher considers it inappropriate to participate in this study
Study Design
Total Participants: 30
Study Start date:
December 01, 2021
Estimated Completion Date:
December 31, 2025
Connect with a study center
Haikou People's Hospital
Haikou,
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.